ibrutinib + omeprazole

The combination of **ibrutinib** and **omeprazole** is primarily utilized in clinical pharmacology and drug-drug interaction (DDI) studies. Ibrutinib is a first-in-class, irreversible inhibitor of **Bruton's tyrosine kinase (BTK)**, used to treat various B-cell malignancies. Omeprazole is a **proton pump inhibitor (PPI)** that increases gastric pH. Because ibrutinib exhibits pH-dependent solubility—being more soluble at lower pH—co-administration with acid-reducing agents like omeprazole can significantly alter its pharmacokinetics. Clinical studies have demonstrated that omeprazole can reduce the peak plasma concentration (Cmax) and the area under the curve (AUC) of ibrutinib. These investigations are critical for establishing clinical guidelines regarding the use of PPIs in patients receiving ibrutinib therapy, often concluding that while exposure is reduced, the interaction may not necessitate dose adjustments in all clinical settings, though monitoring or alternative acid-reducing strategies may be considered.

Brand names

Imbruvica + PrilosecImbruvica + Losec

Other names

ibrutinib and omeprazoleibrutinib/omeprazole